We speculate that the CAD risk variants decrease expression of CDKN2A and CDKN2B, which leads to activation of CDK4, CDK6, and downstream transcription factors, including E2F1, E2F4 and Sp1, and to altered expression of their target genes. The gene discussed is CDKN2B; the disease is coronary artery disorder.